Bessemer Group Inc. Has $8.97 Million Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Bessemer Group Inc. grew its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 10.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 97,167 shares of the biopharmaceutical company’s stock after purchasing an additional 9,573 shares during the quarter. Bessemer Group Inc.’s holdings in Gilead Sciences were worth $8,974,000 as of its most recent SEC filing.

A number of other large investors also recently made changes to their positions in GILD. FMR LLC increased its position in Gilead Sciences by 21.6% during the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company’s stock worth $3,724,306,000 after buying an additional 7,157,113 shares during the period. Wellington Management Group LLP increased its position in Gilead Sciences by 3.1% during the fourth quarter. Wellington Management Group LLP now owns 35,659,007 shares of the biopharmaceutical company’s stock worth $3,293,822,000 after acquiring an additional 1,058,331 shares during the period. Geode Capital Management LLC increased its position in Gilead Sciences by 2.7% during the fourth quarter. Geode Capital Management LLC now owns 28,289,917 shares of the biopharmaceutical company’s stock worth $2,608,337,000 after acquiring an additional 749,047 shares during the period. Norges Bank acquired a new stake in Gilead Sciences in the 4th quarter worth about $1,789,254,000. Finally, Invesco Ltd. grew its position in shares of Gilead Sciences by 12.9% during the 4th quarter. Invesco Ltd. now owns 11,277,915 shares of the biopharmaceutical company’s stock worth $1,041,741,000 after purchasing an additional 1,292,399 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Insider Activity at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total value of $228,375.00. Following the transaction, the chief financial officer now owns 129,873 shares in the company, valued at $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 302,785 shares of company stock worth $30,503,250 over the last ninety days. Insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Down 3.7 %

NASDAQ:GILD opened at $101.40 on Friday. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $119.96. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The company has a market cap of $126.26 billion, a PE ratio of 274.05, a P/E/G ratio of 0.71 and a beta of 0.32. The firm’s 50 day simple moving average is $108.23 and its 200 day simple moving average is $96.64.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Investors of record on Friday, March 14th were paid a $0.79 dividend. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a dividend yield of 3.12%. The ex-dividend date of this dividend was Friday, March 14th. Gilead Sciences’s payout ratio is currently 854.05%.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on GILD. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. Oppenheimer upped their target price on Gilead Sciences from $115.00 to $132.00 and gave the company an “outperform” rating in a research report on Tuesday, March 4th. Deutsche Bank Aktiengesellschaft raised Gilead Sciences from a “hold” rating to a “buy” rating and increased their target price for the stock from $80.00 to $120.00 in a report on Tuesday, February 18th. Royal Bank of Canada upped their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a research report on Wednesday, February 12th. Finally, Wells Fargo & Company raised their target price on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. Eleven investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $105.12.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.